Isoray (NYSEAMERICAN:ISR) announced its earnings results on Monday. The healthcare company reported ($0.01) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.01), MarketWatch Earnings reports. Isoray had a negative return on equity of 15.33% and a negative net margin of 36.52%. During the same period in the previous year, the company posted ($0.02) EPS.
NYSEAMERICAN:ISR traded down $0.01 during trading hours on Wednesday, reaching $0.64. The company’s stock had a trading volume of 3,101 shares, compared to its average volume of 6,261,360. The stock has a market cap of $90.93 million, a P/E ratio of -13.00 and a beta of 1.02. Isoray has a 12 month low of $0.35 and a 12 month high of $2.81. The firm has a 50 day simple moving average of $0.45.
An institutional investor recently raised its position in Isoray stock. Morgan Stanley increased its stake in shares of Isoray, Inc. (NYSEAMERICAN:ISR) by 3,364.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 76,224 shares of the healthcare company’s stock after buying an additional 74,024 shares during the quarter. Morgan Stanley owned about 0.05% of Isoray worth $61,000 as of its most recent SEC filing. Institutional investors and hedge funds own 12.46% of the company’s stock.
Isoray Company Profile
IsoRay, Inc is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors.
Featured Story: Trading signals using Bollinger bands
Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with MarketBeat.com's FREE daily email newsletter.